

## Comprehensive Insights Of The Global Zynteglo market: Key Drivers, Trends, Growth Opportunities, Forecast For 2025-2034

The Business Research Company's Zynteglo Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034

LONDON, GREATER LONDON, UNITED KINGDOM, February 11, 2025 /EINPresswire.com/ -- The zynteglo market size has been showing



significant growth recently. From a robust figure of \$XX million in 2024, it is projected to grow to \$XX million in 2025 at a compound annual growth rate CAGR of XX%. Several factors contribute to this growth during the historic period: increase in rare genetic disorders, the growing adoption of personalized medicine, increased investment in gene therapy research, increased regulatory

approvals for gene therapies, and increasing prevalence of various chronic diseases.



Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

The Business Research company

Get Your Free Sample Market Report:

https://www.thebusinessresearchcompany.com/sample.as px?id=20436&type=smp

In the next few years, the zynteglo market size is expected to see an impressive CAGR of XX% and is predicted to reach \$XX million in 2029. The forecast period promises significant developments attributed to the rising incidence

of thalassemia, the rise in healthcare infrastructure, the growing patient population for rare diseases, the growing focus on long-term treatment solutions, and the rising acceptance of costly treatments. Additionally, the forecast period predicts advancements in genetic editing technology, developing advanced treatments, the integration of patient data to personalize treatments, innovation in clinical trials, and the integration of cutting-edge gene-editing technologies.

One of the principal drivers of the growth in the zynteglo market is the rapidly rising incidence of

thalassemia. Thalassemia, a group of inherited blood disorders characterized by the body's inadequate production of hemoglobin, leads to anemia. The rise can be attributed to factors such as high carrier rates in specific populations, genetic inheritance through consanguineous marriages, increased migration, lack of awareness and screening, and improved diagnosis and survival rates. Zynteglo helps reduce the incidence of thalassemia by offering a one-time gene therapy that enables patients to produce healthy hemoglobin, eliminating the potential need for regular blood transfusions. For instance, the American Society of Hematology, a US-based professional organization, noted in November 2024 that the prevalence of beta-thalassemia was approximately 3,665 cases in 2023, corresponding to a rate of 1.07 per 100,000 individuals, thereby affirming the significant push to the growth of the zynteglo market.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/zynteglo-global-market-report

Major companies contributing to the zynteglo market's robust growth include Bluebird bio Inc. The key trend in the market includes developing innovative therapies, such as gene therapies, to treat genetic disorders with long-term efficacy. A good example is Bluebird Bio Inc., a US-based biotechnology company, which received FDA approval in August 2022 for ZYNTEGLO betibeglogene autotemcel, a novel one-time gene therapy designed to treat beta-thalassemia, a genetic blood disorder. This approval was a milestone in gene therapy, as ZYNTEGLO became the first ex-vivo lentiviral vector gene therapy approved by the FDA to treat beta-thalassemia. The therapy works by modifying a patient's stem cells to produce functional hemoglobin, potentially eliminating the need for regular red blood cell transfusions and iron chelation therapy.

The <u>zynteglo market segments</u> detailed in this report are:

1 By Indication: Beta -Thalassemia; Sickle Cell Disease

2 By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

3 By End User: Adult; Pediatric; Geriatric

Market insights show North America as the largest region in the zynteglo market in 2024. The report thoroughly covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Similar reports available for perusal by <u>The Business Research Company</u>:

Nucleic Acid Based Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report Cell and Gene Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has established a reputation for offering comprehensive, data-rich research and insights. With the possession of 1,500,000 datasets, the inclusion of in-depth secondary research, and the unique insights from industry leaders, you can obtain the information you need to stay ahead in the game.

## Contact us at:

The Business Research Company: <a href="https://www.thebusinessresearchcompany.com/">https://www.thebusinessresearchcompany.com/</a>

Americas +1 3156230293 Asia +44 2071930708 Europe +44 2071930708 Email us at info@tbrc.info

Follow us on:

LinkedIn: <a href="https://in.linkedin.com/company/the-business-research-company/">https://in.linkedin.com/company/the-business-research-company/</a> YouTube: <a href="https://www.youtube.com/channel/UC24\_fl0rV8cR5DxlCpgmyFQ">https://www.youtube.com/channel/UC24\_fl0rV8cR5DxlCpgmyFQ</a>

Global Market Model: <a href="https://www.thebusinessresearchcompany.com/global-market-model">https://www.thebusinessresearchcompany.com/global-market-model</a>

Oliver Guirdham
The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/784986612

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.